Sectors

Data Insights

Venglustat malate by Sanofi for Gaucher Disease Type III: Likelihood of Approval

Data Insights

LIOCYXM-004 by Lion TCR for Hepatocellular Carcinoma: Likelihood of Approval

Data Insights

EVX-02 by Evaxion Biotech for Melanoma: Likelihood of Approval

Data Insights

SBT-101 by SwanBio Therapeutics for Adrenomyeloneuropathy (AMN): Likelihood of Approval

Data Insights

TDM-105795 by Technoderma Medicines for Androgenic Alopecia: Likelihood of Approval

Data Insights

(Chlorthalidone + losartan) by Laboratorios Silanes for Idiopathic (Essential) Hypertension: Likelihood of Approval

Data Insights

SHJ-002 by Sunhawk Vision Biotech for Keratoconjunctivitis Sicca (Dry Eye): Likelihood of Approval

Data Insights

Alimta by Eli Lilly and Co for Chordoma: Likelihood of Approval

Clinical Trials

News

Does Southeast Asia have a growing role in vaccine development?

News

AlloVir and Kalaris enter merger to advance retinal disease therapies

News

Invenra’s antibody gains US FDA designations for neuroblastoma treatment

Drug Manufacturers

Features

Injectables manufacturing ushers in a new era of accessibility

Natasha Spencer-Jolliffe

Analyst Comment

US Election: In close race, tiny Senate majority, not President, will hold power

News

GSK pumps up to $800m for US manufacturing site upgrade

Therapy Area

News

KM Biologics’ mpox vaccine approved for emergency use by WHO

News

Tris Pharma receives ex-US approvals for ADHD treatments

News

Pharmanovia signs license agreement for Lindis Biotech’s catumaxomab

Pricing and Market Access

Analyst Comment

South Korean pricing reform suggests more flexible drug reimbursement negotiations

Analyst Comment

Unresolved clawback issues obstruct Greece’s potential pharmaceutical framework agreement

GlobalData Healthcare

Analyst Comment

Keytruda and Opdivo: a decade review

Sign up to the newsletter: In Brief

I would also like to subscribe to:

Pharma Technology Focus : Focus (monthly)

Thematic Take (monthly)

Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close